Search - tctmd.com

Displaying 441 - 460 of 696

Sort: Relevancy | Date

Presentation PCI Outcomes 2013

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Presenter: Dominick J. Angiolillo

March 07, 2013

News Daily News

Transcatheter Mitral Valve-in-Valve Procedure Benefits Inoperable Patients

Caitlin E. Cox

March 03, 2013

News Industry News

Medtronic Approved to Update Resolute Integrity Stent’s ‘CE’ Mark Labeling on Dual Antiplatelet Therapy

March 03, 2013

News Daily News

Un Documento de la ESC Orienta sobre el Uso Doble de IBP y Antitrombóticos

Caitlin E. Cox

February 27, 2013

News Daily News

ESC Position Paper Offers Guidance on Dual PPI and Antithrombotic Use

Caitlin E. Cox

February 27, 2013

News Daily News

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

February 25, 2013

News Daily News

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

February 25, 2013

News Daily News

A-fib—Whether New or Preexisting—Raises Mortality in Patients Undergoing TAVR

Jason Kahn

February 11, 2013

News Daily News

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Caitlin E. Cox

February 07, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

The REMEDEE OCT study: A prospective randomized study of the early vascular healing of a novel Dual Therapy Stent in comparison with an everolimus eluting stent

Presenter: Ulf Landmesser, William Wijns, Emanuele Barbato, Pasi Karjalainen, Robbert de Winter, Stefan Verheye, Jonathan Hill, Wojciech Wojakowski, Erik Ligtenberg, Stephen Rowland, Hiram Bezerra, Marco Costa

January 31, 2013

Presentation TCT 2013

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Presenter: Laura Mauri, Gabriel Steg, Alexis Matteau, Edoardo Camenzind, Eric Boersma, Pascal Vranckx, Patrick Serruys, William O'Neill, Robert Yeh, William Wijns

January 31, 2013

News Daily News

BMS vs. MIDCAB at 10 Years: Results Similar for LAD Disease, TVR Higher with PCI

Jason Kahn

January 24, 2013

News Conference News Cell Therapy 2013

G-CSF Shows Positive Safety, Efficacy Signals After STEMI in Preliminary Studies

January 23, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

Presentation

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Presenter: Marco Valgimigli

January 16, 2013

News Daily News

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

L.A. McKeown

January 13, 2013

News Daily News

JACC Letter: Hypothermia Therapy May Increase Stent Thrombosis Risk

L.A. McKeown

January 06, 2013

News Daily News

Year in Review: Physicians Highlight the Most Important Interventional News of 2012

Caitlin E. Cox

January 02, 2013

Advertisement

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Transcatheter Mitral Valve-in-Valve Procedure Benefits Inoperable Patients

Medtronic Approved to Update Resolute Integrity Stent’s ‘CE’ Mark Labeling on Dual Antiplatelet Therapy

Un Documento de la ESC Orienta sobre el Uso Doble de IBP y Antitrombóticos

ESC Position Paper Offers Guidance on Dual PPI and Antithrombotic Use

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

A-fib—Whether New or Preexisting—Raises Mortality in Patients Undergoing TAVR

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

The REMEDEE OCT study: A prospective randomized study of the early vascular healing of a novel Dual Therapy Stent in comparison with an everolimus eluting stent

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

BMS vs. MIDCAB at 10 Years: Results Similar for LAD Disease, TVR Higher with PCI

G-CSF Shows Positive Safety, Efficacy Signals After STEMI in Preliminary Studies

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Should Duration of Dual Antiplatelet Therapy Depend on the Type and/or Potency of Implanted Stent?

Novel Anti-inflammatory May Reduce Restenosis After BMS in High-Risk Patients

JACC Letter: Hypothermia Therapy May Increase Stent Thrombosis Risk

Year in Review: Physicians Highlight the Most Important Interventional News of 2012

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content